Thermo Fisher Scientific Inc. (NYSE:TMO) – Stock analysts at Jefferies Group raised their Q3 2016 earnings per share estimates for Thermo Fisher Scientific in a research report issued to clients and investors on Tuesday. Jefferies Group analyst B. Couillard now anticipates that the firm will post earnings per share of $1.99 for the quarter, up from their previous estimate of $1.98. Jefferies Group currently has a “Hold” rating on the stock. Jefferies Group also issued estimates for Thermo Fisher Scientific’s FY2017 earnings at $9.20 EPS.

Other analysts also recently issued research reports about the company. Zacks Investment Research upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $172.00 price target for the company in a research report on Thursday. Bank of America Corp. set a $180.00 target price on Thermo Fisher Scientific and gave the stock a “buy” rating in a research report on Friday, October 7th. Goldman Sachs Group Inc. restated a “buy” rating on shares of Thermo Fisher Scientific in a research report on Wednesday, July 6th. Citigroup Inc. boosted their target price on Thermo Fisher Scientific from $160.00 to $182.00 and gave the stock a “buy” rating in a research report on Friday, July 29th. Finally, Mizuho set a $175.00 target price on Thermo Fisher Scientific and gave the stock a “buy” rating in a research report on Thursday, July 28th. Two investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. Thermo Fisher Scientific has a consensus rating of “Buy” and an average target price of $162.37.

Earnings History and Estimates for Thermo Fisher Scientific (NYSE:TMO)

Shares of Thermo Fisher Scientific (NYSE:TMO) opened at 151.71 on Thursday. The firm’s 50-day moving average is $153.51 and its 200-day moving average is $151.02. Thermo Fisher Scientific has a 52-week low of $119.75 and a 52-week high of $160.68. The firm has a market cap of $59.81 billion, a P/E ratio of 30.35 and a beta of 0.97.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Thursday, July 28th. The company reported $2.03 earnings per share for the quarter, beating analysts’ consensus estimates of $2.01 by $0.02. The business earned $4.54 billion during the quarter, compared to the consensus estimate of $4.50 billion. Thermo Fisher Scientific had a net margin of 11.35% and a return on equity of 14.70%. The company’s revenue for the quarter was up 6.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.84 EPS.

A number of large investors have recently modified their holdings of TMO. Franklin Resources Inc. boosted its stake in Thermo Fisher Scientific by 0.5% in the first quarter. Franklin Resources Inc. now owns 289,317 shares of the company’s stock worth $40,965,000 after buying an additional 1,374 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in Thermo Fisher Scientific by 72.3% in the first quarter. JPMorgan Chase & Co. now owns 1,953,935 shares of the company’s stock worth $276,658,000 after buying an additional 820,110 shares in the last quarter. NN Investment Partners Holdings N.V. bought a new stake in Thermo Fisher Scientific during the first quarter worth approximately $16,326,000. Adell Harriman & Carpenter Inc. boosted its stake in Thermo Fisher Scientific by 2.2% in the first quarter. Adell Harriman & Carpenter Inc. now owns 2,597 shares of the company’s stock worth $368,000 after buying an additional 55 shares in the last quarter. Finally, Palisade Capital Management LLC NJ boosted its stake in Thermo Fisher Scientific by 292.9% in the first quarter. Palisade Capital Management LLC NJ now owns 20,039 shares of the company’s stock worth $2,837,000 after buying an additional 14,939 shares in the last quarter. 87.38% of the stock is currently owned by institutional investors.

In related news, Director C Martin Harris sold 390 shares of the company’s stock in a transaction on Friday, August 5th. The stock was sold at an average price of $157.33, for a total value of $61,358.70. Following the sale, the director now directly owns 4,648 shares of the company’s stock, valued at $731,269.84. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Marc N. Casper sold 30,000 shares of the company’s stock in a transaction on Thursday, September 1st. The stock was sold at an average price of $151.17, for a total value of $4,535,100.00. Following the completion of the sale, the chief executive officer now directly owns 308,647 shares in the company, valued at $46,658,166.99. The disclosure for this sale can be found here. 0.52% of the stock is owned by corporate insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company is a provider of analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. The company operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

5 Day Chart for NYSE:TMO

Receive News & Stock Ratings for Thermo Fisher Scientific Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc. and related stocks with our FREE daily email newsletter.